Zimeldine treatment of obsessive-compulsive disorder. Biological and neuropsychological aspects.
Six patients with Obsessive-Compulsive Disorder (DSM III) were treated in an open uncontrolled trial with Zimeldine, for 8 weeks. All six patients had cognitive deficits before treatment. Five patients improved on the clinical symptoms. Four of these showed pronounced amelioration of their cognitive deficits.
D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000523:psychology; D011581:Psychological Tests; D015031:Zimeldine / Q000627:therapeutic use*
D015031:Zimeldine